WESTMINSTER, Colo., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced the recent launch of the Biotivity™ A/C Plus Membrane, a growth factor rich membrane used for site coverage and protection from the oral environment in a variety of dental applications. The membrane is now available in the United States.
Dental bone grafting procedures, in conjunction with protective barrier membranes, are used to repair or reconstruct the jaw and to provide a foundation for dental implant placement. This launch broadens ZimVie’s presence in the dental biomaterials market, expanding into the large growth factor segment. ZimVie’s Biotivity A/C Plus Membrane is a barrier membrane containing a variety of growth factors, cytokines, chemokines, and hyaluronic acid shown to facilitate wound healing.1-3
“We remain focused on bringing new products to market to meet customer needs and ensure their teams have the best solutions at their disposal,” said Indraneel Kanaglekar, SVP and President of ZimVie Dental. “Biotivity’s triple-layer structure is thicker than conventional A/C membranes and may contribute to enhanced conformability and growth factor content.”1, 2, 4
For more information on ZimVie's Dental implants, suite of connected solutions, and continuing education, please visit www.zimvie.com.
About Biotivity™ A/C Plus Membrane
Biotivity™ A/C Plus Membrane is a growth factor-charged membrane derived from human placental tissue. Consisting of the amnion, intermediate, and chorion layers, Biotivity A/C Plus is minimally manipulated using proprietary processing that preserves natural mechanical properties, elasticity, growth factors, cytokines, and other biological enhancers.5, 6 The product has been sterilized using the Excellion® Process, and terminally sterilized with Electron-Beam irradiation. Unlike other A/C membranes available on the market Biotivity A/C Plus is not treated with antibiotics during the processing.5, 7
About ZimVie
ZimVie is a global life sciences leader in the dental and spine markets that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures. The company was founded in March 2022 as an independent, publicly traded spin-off of the Dental and Spine business units of Zimmer Biomet to breathe new life, dedicated energy, and strategic focus to its portfolio of trusted brands and products. From its headquarters in Westminster, Colorado, and additional facilities around the globe, the company serves customers in over 70 countries worldwide with a robust offering of dental and spine solutions, including differentiated product platforms supported by extensive clinical evidence. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see ZimVie’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in ZimVie’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.
Media Contact Information:
ZimVie
Laura Driscoll • Laura.Driscoll@ZimVie.com
(774) 284-1606
ZimVie
Allison Johnson • Allison.Johnson@ZimVie.com
(774) 266-8046
Investor Contact Information:
Gilmartin Group LLC
Marissa Bych • Marissa@gilmartinir.com
References:
1. Malak T.M. et al. Placenta (1993) 14:385-406.
2. Roy A., Griffiths S. J Tissue Eng Regen Med (2020) 14:1126-1135.
3. Bryant-Greenwood G.D. Placenta (1998) 19:1-11.
4. Hieber A.D. et al. Placenta (1997) 18:301-312.
5. Data on file with manufacturer.
6. Koizumi N. et al. Curr Eye Res (2000) 20:173-177.
7. Biotivity A/C Plus Membrane IFU Rev. 03.
